CVS Health Corporation CVS
Composite 48/100; the shares have moved about 31% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 34/100 — a moderate mark against it.
Momentum ranks 74/100 — a moderate point in its favour. Income ranks 69/100 — a moderate point in its favour. Valuation ranks 60/100 — a slight point in its favour.
Quality ranks 34/100 — a moderate mark against it. Growth ranks 34/100 — a moderate mark against it. Balance-sheet strength ranks 40/100 — a slight mark against it.
What the company does CVS Health operates in three segments: Health Care Benefits (insurance products and Medicare/Medicaid plans), Health Services (pharmacy benefit management and clinical services), and Retail/Long-term care (pharmacies and clinics). It serves employers, insurers, government plans, and consumers through integrated health solutions.
Key financials CVS reports ROE 6.2%, ROA 3.0%, and ROCE 5.3%. Margins are tight: gross 13.6%, operating 3.9%, net 1.2%. Revenue grew 7.8% while EPS fell -62.6%. Leverage is moderate (Debt/Equity 0.96) but liquidity is weak (Current ratio 0.87). Dividend yield is 2.7% with a 33.9% payout ratio.
Stock health Momentum is positive: +37.66% over 12m, +23.08% over 6m, +9.73% over 3m, but -11.27% below the 52w high. RSI(14) is neutral at 52.30. Sideravia scores Quality 34.1 and Growth 34.2, but Valuation 59.5 and Momentum 73.6 are stronger.
Price vs fair value CVS trades at a discount of 18.90% versus the analyst mean target of 116.08. - Recent headlines highlight partnerships (LOVB naming CVS as Health & Wellness Partner) and balance sheet improvements (deleveraging support) as catalysts. - Analyst mean target implies 18.90% upside from the current price of 97.60. - Sideravia’s Valuation percentile of 59.5 suggests the stock is attractively valued relative to its screened universe.
Looking forward Forward P/E of 12.87 and PEG of 0.14 indicate expectations for earnings recovery. FCF yield of 6.5% supports income potential. Execution on deleveraging and integrated care growth will be key to closing the valuation gap.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.